89976-48-7 Usage
Description
N-(4-iodo-benzenesulfonyl)-glycine, with the molecular formula C8H8INO4S and a molecular weight of 307.12 g/mol, is an organic compound characterized by a sulfonamide functional group and an iodine atom attached to a benzene ring. It is widely recognized in the field of medicinal chemistry for its role as a building block in the synthesis of pharmaceuticals and biologically active compounds. Additionally, it has been investigated for its potential therapeutic applications, including its use as an inhibitor of protein-protein interactions and a modulator of enzyme activity. N-(4-iodo-benzenesulfonyl)-glycine serves as a valuable synthetic intermediate in the development of new drug candidates and has demonstrated promise in various biological and pharmacological studies.
Uses
Used in Pharmaceutical Synthesis:
N-(4-iodo-benzenesulfonyl)-glycine is used as a building block for the synthesis of various pharmaceuticals and biologically active compounds. Its unique structure and functional groups make it a versatile component in the creation of new drug candidates.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, N-(4-iodo-benzenesulfonyl)-glycine is used as a research tool to study its potential therapeutic applications. It has been investigated for its ability to inhibit protein-protein interactions and modulate enzyme activity, which could lead to the development of novel treatments for various diseases.
Used in Drug Development:
N-(4-iodo-benzenesulfonyl)-glycine is utilized as a valuable synthetic intermediate in the development of new drug candidates. Its unique properties and potential applications make it a promising starting point for the creation of innovative pharmaceuticals.
Used in Biological and Pharmacological Studies:
N-(4-iodo-benzenesulfonyl)-glycine is also employed in various biological and pharmacological studies to explore its potential effects on different biological systems and to better understand its mechanisms of action. This research can contribute to the advancement of medical knowledge and the development of new therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 89976-48-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,9,7 and 6 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 89976-48:
(7*8)+(6*9)+(5*9)+(4*7)+(3*6)+(2*4)+(1*8)=217
217 % 10 = 7
So 89976-48-7 is a valid CAS Registry Number.
89976-48-7Relevant articles and documents
Protease inhibitors - Part 5. Alkyl/arylsulfonyl- and arylsulfonylureido-/arylureido- glycine hydroxamate inhibitors of Clostridium histolyticum collagenase
Scozzafava, Andrea,Supuran, Claudiu T.
, p. 299 - 307 (2007/10/03)
Reaction of alkyl/arylsulfonyl halides with glycine afforded a series of derivatives which were first N-benzylated by treatment with benzyl chloride, and then converted to the corresponding hydroxamic acids with hydroxylamine in the presence of carbodiimide derivatives. Other derivatives were obtained by reaction of N-benzyl-glycine with aryl isocyanates, arylsulfonyl isocyanates or benzoyl isothiocyanate, followed by conversion of their COOH group into the CONHOH moiety, as mentioned above. The 90 new compounds reported here were assayed as inhibitors of the Clostridium histolyticum collagenase (EC 3.4.24.3), a zinc enzyme which degrades triple helical regions of native collagen. The prepared hydroxamate derivatives were generally 100-500 times more active than the corresponding carboxylates. In the series of synthesized hydroxamates, substitution patterns leading to the best inhibitors were those involving perfluoroalkylsulfonyl- and substituted- arylsulfonyl moieties, such as pentafluorophenylsulfonyl, 3- and 4- carboxyphenylsulfonyl-, 3-trifluoromethyl-phenylsulfonyl or 1- and 2-naphthyl among others. Thus, it seems that similarly to the matrix metalloproteinase (MMP) hydroxamate inhibitors, Clostridium histolyticum collagenase inhibitors should incorporate hydrophobic moieties at the P1, and P2, sites, whereas the α-carbon substituent may be a small and compact moiety (such as H. for the Gly derivatives reported here). Such compounds might lead to the design of collagenase inhibitor-based drugs useful as anti-cancer, anti-arthritis or anti-bacterial agents for the treatment of corneal keratitis. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
